アキューメン・ファーマシューティカルズに関するコメント

$アキューメン・ファーマシューティカルズ(ABOS.US)$
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...

$アキューメン・ファーマシューティカルズ(ABOS.US)$ Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved

$アキューメン・ファーマシューティカルズ(ABOS.US)$
slowly moving up

$アキューメン・ファーマシューティカルズ(ABOS.US)$ announced that it has entered into a senior secured loan and security agreement  with K2 HealthVentures, a healthcare-focused specialty finance company.

$アキューメン・ファーマシューティカルズ(ABOS.US)$ Just off ATL ( you know how i likes me some bottom bouncers, hehehe ) Earnings out Monday 11/13/23 BMO!  But mainly for the following! Phase 1 data on ACU193/INTERCEPT-AD was very promising! The Recent collaboration & License agreement with HALOZYME Could make this Alzheimer’s treatment a game changer for patients by allowing the delivery of the drug Subcutaneously instead of IV? Which would be much more convenient and less inva...

$アキューメン・ファーマシューティカルズ(ABOS.US)$ Acumen Pharmaceuticals, Inc. And Halozyme Enter Global Collaboration And License Agreement To Develop Subcutaneous Formulation Of ACU193 With ENHANZE Technology

$アキューメン・ファーマシューティカルズ(ABOS.US)$ im out first… doesnt look good to me…